Barry S. Coller, M.D.
Chair, Medical & SAB, Co-Founder, and Inventor of RUC-4
Barry S. Coller, M.D., is Vice President for Medical Affairs, David Rockefeller Professor, Head of the Allen and Frances Laboratory of Blood and Vascular Biology, and Physician-in-Chief at The Rockefeller University. He is an expert on the basic molecular mechanisms involved in blood clotting and thrombosis. His research accomplishments include the development of a monoclonal antibody to platelets that was developed into the drug abciximab (ReoPro). He is also the inventor of RUC-4.
Dr. Coller is a member of the Institute of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences. He is a past president of the American Society of Hematology and was founding president of the Society for Clinical and Translational Science.
Robert S. Hillman, Ph.D.
President & CEO, Co-Founder .
Robert S. Hillman, Ph.D., is a biomedical engineer and successful serial medtech entrepreneur/inventor. He studied at Stanford, MIT, and the Swiss Federal Institute of Technology (ETH). Early in his career, Dr. Hillman led the development of the GenESA System, the first drug-device combination cleared by the FDA for diagnosing Coronary Artery Disease.
Dr. Hillman was co-founder at Accumetrics, Biotrack and ActivX Biosciences, and a key early employee at Gensia Inc., and TEM Systems. At Accumetrics, he developed and received worldwide regulatory clearance for the VerifyNow platform, which was based on technology licensed from Mount Sinai from Dr. Coller’s laboratory, establishing the company as a leader in platelet function testing.
Member, Board of Directors Co-Founder
Andreas Ritzi is CFO of Cadorit AG, a Swiss-based investment Company. He is a financial specialist and accomplished entrepreneur. He has a MBA from the University of St. Gallen and a MSc in Finance from the London Business School.
Member, Board of Directors .
Jack Lief co-founded Arena Pharmaceuticals, Inc. and served as its President and Chief Executive Officer. He served as Chairman of the Board of Directors of BIOCOM and is an Executive Board Member of BIOCOM. He also held senior business development positions at Cephalon, Alpha Therapeutics, and Abbott Laboratories.
Peter B. Finn
Corporate Secretary .
Peter Finn is Partner and Chair, Corporate at Rubin and Rudman, LLP. He is principally devoted to representing biotechnology and high technology companies in all aspects of corporate law, licensing, and financing and has assisted in the launch of more than 50 biotech companies.